CONTACT
+91 80 2808 2808
info@biocon.com

Biocon Receive Decentralized Procedure Approval for Liraglutide in European Union

  • Posted by: BIOCON

EMA’s CHMP recommends approval of Biocon Biologics’ YESINTEK®, biosimilar to J&J’s Stelara®

  • Posted by: BIOCON

Kiran Mazumdar-Shaw Honored by ISQ with ‘Jamsetji Tata Award’ for Pioneering Biosciences Movement in India

  • Posted by: BIOCON

Biocon Biologics Recognized as Asia IP Elite for 2024 by IAM, Cementing Leadership in Intellectual Property Excellence

  • Posted by: BIOCON

Biocon Receives EIR with VAI Status from US FDA for Bengaluru API Facility Site-2

  • Posted by: BIOCON

U.S. FDA Approves Biocon Biologics’ YESINTEK™, Bmab 1200 biosimilar to J&J’s Stelara® (Ustekinumab)

  • Posted by: BIOCON

Biocon Celebrates 46th Founder’s Day with Anthem Launch, Walkathon, Leadership Talk and Experience Center Inauguration

  • Posted by: BIOCON

Biocon Biologics Supports Diabetes Africa to Drive Progress in Embedding Specialist Nurses in Diabetes Care in Ethiopia

  • Posted by: BIOCON

Biocon Academy Achieves 100% Placement within 2.5 hours for Quality Control Analytical Program

  • Posted by: BIOCON

USFDA Classifies Biocon Biologics’ Biocon Park Site in Bengaluru, India as Voluntary Action Initiated (VAI)

  • Posted by: BIOCON
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>